Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant + cisplatin + IMRT in locally advanced head and neck cancer
NCT06056310Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of xevinapant in squamous cell carcinoma of the head and neck (HNSCC), sponsored by EMD Serono. Primary endpoint: Dose Limiting Toxicity-Like Events at 5 weeks. Started Jan 2024; status: terminated.
02
Drugs
xevinapant
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06056310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056310.